Literature DB >> 9298003

Emergence of a carbapenem-resistant Klebsiella pneumoniae.

F M MacKenzie, K J Forbes, T Dorai-John, S G Amyes, I M Gould.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9298003     DOI： 10.1016/s0140-6736(05)62567-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  30 in total

1.  Expression of SHV-2 beta-lactamase and of reduced amounts of OmpK36 porin in Klebsiella pneumoniae results in increased resistance to cephalosporins and carbapenems.

Authors:  Brendan Crowley; Vicente J Benedí; Antonio Doménech-Sánchez
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 2.  Quarantine, isolation, and cohorting: from cholera to Klebsiella.

Authors:  Laura H Rosenberger; Lin M Riccio; Kristin Turza Campbell; Amani D Politano; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2012-04       Impact factor: 2.150

3.  Findings from an outbreak of carbapenem-resistant Klebsiella pneumoniae emphasize the role of antibiotic treatment for cross transmission.

Authors:  Stefan Borgmann; Yvonne Pfeifer; Laura Becker; Beate Rieß; Rabea Siegmund; Ulrich Sagel
Journal:  Infection       Date:  2017-11-24       Impact factor: 3.553

Review 4.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

5.  Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae.

Authors:  L Martínez-Martínez; A Pascual; S Hernández-Allés; D Alvarez-Díaz; A I Suárez; J Tran; V J Benedí; G A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

6.  Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1.

Authors:  R Kirk; A Ratcliffe; G Noonan; M Uosis-Martin; D Lyth; O Bardell-Cox; J Massam; P Schofield; S Hindley; D R Jones; J Maclean; A Smith; V Savage; S Mohmed; C Charrier; A-M Salisbury; E Moyo; R Metzger; N Chalam-Judge; J Cheung; N R Stokes; S Best; M Craighead; R Armer; A Huxley
Journal:  RSC Med Chem       Date:  2020-09-18

7.  Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan.

Authors:  Chin-Fang Su; Chien Chuang; Yi-Tsung Lin; Yu-Jiun Chan; Jung-Chung Lin; Po-Liang Lu; Ching-Tai Huang; Jann-Tay Wang; Yin-Ching Chuang; L Kristopher Siu; Chang-Phone Fung
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-14       Impact factor: 3.267

8.  Risk factors for bacteriuria with carbapenem-resistant Klebsiella pneumoniae and its impact on mortality: a case-control study.

Authors:  S Shilo; M V Assous; T Lachish; P Kopuit; T Bdolah-Abram; A M Yinnon; Y Wiener-Well
Journal:  Infection       Date:  2012-12-28       Impact factor: 3.553

9.  Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study.

Authors:  Yang Jiao; Yanghua Qin; Jiajun Liu; Qiang Li; Yuchao Dong; Yan Shang; Yi Huang; Rui Liu
Journal:  Pathog Glob Health       Date:  2015-02-24       Impact factor: 2.894

10.  Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.

Authors:  Leanne B Gasink; Paul H Edelstein; Ebbing Lautenbach; Marie Synnestvedt; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2009-12       Impact factor: 3.254
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.